BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Izalontamab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Izalontamab\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06668961-2265@assetmemo.bio
DTSTAMP:20261121T005725Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Izalontamab: Phase 2 readout est. (NCT06668961)
DESCRIPTION:Izalontamab\, phase 2\, Head and Neck Squamous Cell Carcinoma.\
 nStudy: A Study of SI-B001+SI-B003 Combined With Platinum-based Chemothera
 py as First-line Treatment in Patients With Recurrent or Metastatic Head a
 nd Neck Squamous Cell Carcinoma\nEstimated primary completion: November 20
 26. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/izalontamab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06668961
URL:https://assetmemo.bio/drug/izalontamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05668858-2265@assetmemo.bio
DTSTAMP:20261121T005725Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Izalontamab: Phase 1/2 readout est. (NCT05668858)
DESCRIPTION:Izalontamab\, phase 1/2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: A Study of SI-B001+SI-B003± Chemotherapy in Patients With Local
 ly Advanced or Metastatic Head and Neck Squamous Cell Carcinoma\nEstimated
  primary completion: December 2026. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/izalontamab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT05668858
URL:https://assetmemo.bio/drug/izalontamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05949606-2265@assetmemo.bio
DTSTAMP:20261121T005725Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Izalontamab: Phase 1/2 readout est. (NCT05949606)
DESCRIPTION:Izalontamab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advan
 ced or Metastatic Non-small Cell Lung Cancer\nEstimated primary completion
 : December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/izal
 ontamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05949606
URL:https://assetmemo.bio/drug/izalontamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05054439-2265@assetmemo.bio
DTSTAMP:20261121T005725Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Izalontamab: Phase 2 readout est. (NCT05054439)
DESCRIPTION:Izalontamab\, phase 2\, Head and Neck Squamous Cell Carcinoma.\
 nStudy: A Clinical Study of SI-B001 in Combination With Paclitaxel/Docetax
 el in the Treatment of Recurrent and Metastatic HNSCC\nEstimated primary c
 ompletion: December 2026. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/izalontamab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05054439
URL:https://assetmemo.bio/drug/izalontamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
